Any previous treatments for active CSC;
Previous prescription of mineralocorticoid receptor antagonists, for cCSC or for other diseases;
Current treatment with corticosteroids (topical or systemic), corticosteroid use within 3 months before possible start of trial treatment, or anticipated start of corticosteroid treatment within the first 2 years from the start of the trial period;
Evidence of another diagnosis that can explain serous SRF or visual loss;
Best-corrected visual acuity < 20/200 (Snellen equivalent);
Profound chorioretinal atrophy in central macular area on ophthalmoscopy and OCT;
Myopia > 6D;
Visual loss and/or serous detachment on OCT < 6 weeks;
Continuous and/or progressive visual loss > 18 months or serous detachment on OCT > 18 months;
No hyperfluorescence on ICGA;
Intraretinal edema on OCT;
(relative) Contraindications for FA or ICGA;
(relative) Contraindications for photodynamic treatment (pregnancy, porphyria, severely disturbed liver function). Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening
(relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent). Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;
Soft drusen in treated eye or fellow eye, signs of choroidal neovascularization on ophthalmoscopy and/or FA/ICGA of the study eye.

NCT03079141_exc_T1
Qualifier
active
NCT03079141_exc_T2
Condition
CSC
NCT03079141_exc_T3
Procedure
treatments
NCT03079141_exc_T4
Temporal
previous
NCT03079141_exc_T5
Temporal
Previous
NCT03079141_exc_T6
Drug
mineralocorticoid receptor antagonists
NCT03079141_exc_T7
Condition
cCSC
NCT03079141_exc_T8
Condition
other diseases
NCT03079141_exc_T9
Scope
cCSC or for other diseases
NCT03079141_exc_T10
Drug
corticosteroids
NCT03079141_exc_T11
Temporal
Current
NCT03079141_exc_T12
Qualifier
topical
NCT03079141_exc_T13
Qualifier
systemic
NCT03079141_exc_T14
Scope
topical or systemic
NCT03079141_exc_T15
Procedure
corticosteroid use
NCT03079141_exc_T16
Temporal
within 3 months before possible start of trial treatment
NCT03079141_exc_T17
Reference_point
possible start of trial treatment
NCT03079141_exc_T18
Procedure
corticosteroid treatment
NCT03079141_exc_T19
Temporal
within the first 2 years from the start of the trial period
NCT03079141_exc_T20
Reference_point
the first 2 years from the start of the trial period
NCT03079141_exc_T21
Mood
anticipated
NCT03079141_exc_T23
Measurement
Best-corrected visual acuity
NCT03079141_exc_T24
Value
< 20/200
NCT03079141_exc_T25
Qualifier
Profound
NCT03079141_exc_T26
Condition
chorioretinal atrophy
NCT03079141_exc_T27
Qualifier
central macular area
NCT03079141_exc_T28
Procedure
ophthalmoscopy
NCT03079141_exc_T29
Procedure
OCT
NCT03079141_exc_T30
Scope
ophthalmoscopy and OCT
NCT03079141_exc_T31
Measurement
Myopia
NCT03079141_exc_T32
Value
> 6D
NCT03079141_exc_T33
Condition
Visual loss
NCT03079141_exc_T34
Condition
serous detachment
NCT03079141_exc_T35
Procedure
OCT
NCT03079141_exc_T36
Temporal
< 6 weeks
NCT03079141_exc_T37
Scope
Visual loss and/or serous detachment
NCT03079141_exc_T38
Qualifier
Continuous
NCT03079141_exc_T39
Qualifier
progressive
NCT03079141_exc_T40
Condition
visual loss
NCT03079141_exc_T41
Scope
Continuous and/or progressive
NCT03079141_exc_T42
Temporal
> 18 months
NCT03079141_exc_T43
Condition
serous detachment
NCT03079141_exc_T44
Procedure
OCT
NCT03079141_exc_T45
Temporal
> 18 months
NCT03079141_exc_T46
Measurement
ICGA
NCT03079141_exc_T47
Value
hyperfluorescence
NCT03079141_exc_T48
Negation
No
NCT03079141_exc_T49
Condition
Intraretinal edema
NCT03079141_exc_T50
Procedure
OCT
NCT03079141_exc_T51
Condition
Contraindications
NCT03079141_exc_T52
Procedure
FA
NCT03079141_exc_T53
Procedure
ICGA
NCT03079141_exc_T54
Scope
FA or ICGA
NCT03079141_exc_T55
Condition
Contraindications
NCT03079141_exc_T56
Procedure
photodynamic treatment
NCT03079141_exc_T57
Condition
pregnancy
NCT03079141_exc_T58
Condition
porphyria
NCT03079141_exc_T59
Qualifier
severely
NCT03079141_exc_T60
Condition
disturbed liver function
NCT03079141_exc_T61
Scope
pregnancy, porphyria, severely disturbed liver function
NCT03079141_exc_T62
Scope
Contraindications for photodynamic treatment
NCT03079141_exc_T64
Condition
contraindications
NCT03079141_exc_T65
Drug
eplerenone
NCT03079141_exc_T66
Condition
hyperkalemia
NCT03079141_exc_T67
Condition
abnormal renal clearance
NCT03079141_exc_T68
Measurement
renal clearance
NCT03079141_exc_T69
Value
abnormal
NCT03079141_exc_T70
Condition
severe hepatic insufficiency
NCT03079141_exc_T71
Measurement
Child-Pugh
NCT03079141_exc_T72
Value
C
NCT03079141_exc_T73
Condition
type 2 diabetes mellitus
NCT03079141_exc_T74
Condition
microalbuminuria
NCT03079141_exc_T75
Scope
type 2 diabetes mellitus with microalbuminuria
NCT03079141_exc_T76
Temporal
concomitant
NCT03079141_exc_T77
Drug
potassium supplements
NCT03079141_exc_T78
Drug
potassium-sparing diuretics
NCT03079141_exc_T79
Drug
strong CYP3A4 inhibitors
NCT03079141_exc_T80
Drug
ACE-inhibitor
NCT03079141_exc_T81
Drug
angiotensin receptor blocking agent
NCT03079141_exc_T82
Scope
ACE-inhibitor and an angiotensin receptor blocking agent
NCT03079141_exc_T83
Scope
potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent
NCT03079141_exc_T85
Condition
Soft drusen
NCT03079141_exc_T86
Qualifier
treated eye
NCT03079141_exc_T87
Qualifier
fellow eye
NCT03079141_exc_T88
Scope
treated eye or fellow eye
NCT03079141_exc_T89
Condition
choroidal neovascularization
NCT03079141_exc_T90
Procedure
ophthalmoscopy
NCT03079141_exc_T91
Procedure
FA
NCT03079141_exc_T92
Procedure
ICGA
NCT03079141_exc_T93
Qualifier
study eye
NCT03079141_exc_T94
Scope
ophthalmoscopy and/or FA/ICGA